Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palazestrant in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in Advanced ER+/HER2- Breast Cancer
NCT05508906Phase 1Active, not recruiting
- Sponsor
- Olema Oncology
- Start
- Aug 2022
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of palazestrant in breast cancer (4 arms), sponsored by Olema Oncology. Primary endpoints: Dose Limiting Toxicities at 28 days, Treatment Emergent Adverse Events and Serious Adverse Events and 1 more. Started Aug 2022; status: active, not recruiting.
02
Drugs
palazestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05508906.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05508906.